
Editas Medicine fell 27.5% from $2.58 to $1.87, behind the S&P 500's +11.2%. Its worst day was Jun 2 (−15.6%), and its low came Feb 5 at $1.67.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Editas Medicine closed at its lowest level of the year, 35.5% below where the year started.
−14.6% · S&P 500 −1.2%
EPS of $-0.06 beat the $-0.24 estimate on $24.7M revenue (est. $7.9M).
Story events cover the past 12 months · Times ET
+16.0%, the year's best day · S&P 500 +0.9%
EPS of $-0.26 missed the $-0.25 estimate on $2.8M revenue (est. $6.5M).
+1.3% · S&P 500 +0.8%
Editas Medicine shares rose 15.9%, while the S&P 500 fell 0.0%.
+15.9% · S&P 500 0.0%
Editas Medicine closed at its highest level of the year, 45.3% above where the year started.
+2.7% · S&P 500 −0.5%
EPS of $-0.15 beat the $-0.28 estimate on $11.9M revenue (est. $2.6M).
+5.5% · S&P 500 −0.2%
Editas Medicine shares rose 13.5%, while the S&P 500 rose 0.3%.
+13.5% · S&P 500 +0.3%
EPS of $-0.15 beat the $-0.21 estimate on $10.4M revenue (est. $4.0M).
+7.0% · S&P 500 +2.4%
Where it ended: a close of $1.87 on Nov 16, 2026. Up next: Q4 2026 earnings on Mar 8, 2027 (EPS est. $-0.20, revenue est. $3.5M).
Nothing in the past 12 months.
All EDIT dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for EDIT and SPY from Benzinga historical bars. Not investment advice.